Market Access Position at Novartis Farmacéutica S.A. de C.V.

Novartis Farmacéutica S.A. de C.V. is expanding its commercial operations in Mexico by recruiting a Sales & Marketing Manager for gene therapy within its Market Access division, according to a company job listing dated June 13, 2026. The position focuses on the strategic integration of high-cost innovative medicines into the Mexican healthcare system to increase availability for rare disease patients.

The recruitment drive targets the Market Access functional area, which handles the pricing, reimbursement, and payment schemes required to make advanced therapies accessible to patients. This role is a full-time, regular employment position within the company’s Mexican subsidiary.

Why is Novartis expanding gene therapy market access in Mexico?

Gene therapies represent a shift from chronic treatment to one-time curative interventions, but they carry price tags that often reach millions of dollars per dose. Market access managers are tasked with negotiating these costs with government health agencies and private insurers to ensure the therapies are covered by national health budgets.

According to Novartis corporate strategy filings, the company has prioritized “innovative medicines” and “cell and gene therapy” (CGT) as core growth drivers. In markets like Mexico, this requires specialized personnel who can build value-based pricing models. These models often link payment to the actual clinical outcome of the patient rather than a flat fee per dose.

The move signals a push to move gene therapy products from the clinical pipeline into active commercial distribution within the Latin American region. This requires a bridge between the medical benefits of the drug and the economic realities of the local healthcare infrastructure.

How does this role fit into the Novartis oncology and rare disease pipeline?

The hiring for a gene therapy specialist aligns with Novartis’s broader investment in oncology and rare disease treatments. The company’s pipeline includes advanced cell therapies and gene-editing technologies designed to treat conditions that previously had no viable cure.

By embedding a marketing and sales manager directly within the Market Access team, Novartis is linking the commercialization of these drugs with the regulatory approval process. This ensures that by the time a gene therapy receives health authority approval in Mexico, a reimbursement pathway is already established.

This strategy contrasts with the business model of Sandoz, the generics and biosimilars division that Novartis spun off into a separate entity in late 2023. While Sandoz focuses on high-volume, lower-cost alternatives to off-patent drugs, the Novartis innovative medicines arm focuses on low-volume, high-value therapies for small patient populations.

What challenges face gene therapy adoption in the Mexican market?

The primary obstacle for gene therapy in Mexico is the funding gap. Most public health systems are designed for recurring pharmaceutical spend rather than massive, upfront payments for a single treatment. The Sales & Marketing Manager for Gene Therapy must navigate these budgetary constraints.

Industry data indicates that rare disease patients in emerging markets often face significant delays in accessing CGT due to the lack of established “managed entry agreements.” These are contracts where the pharmaceutical company and the payer share the financial risk if a drug does not perform as expected.

Additionally, the infrastructure for administering gene therapies is limited. These treatments often require specialized certified treatment centers capable of handling complex cell-collection and infusion processes, adding another layer of complexity to the market access strategy.

What happens next for Novartis’s innovative medicines in Mexico?

The appointment of a dedicated manager for gene therapy suggests that Novartis is preparing for the launch or expansion of specific CGT products in the Mexican market. The company’s focus will likely shift toward establishing these value-based agreements with the Mexican government to secure long-term funding for rare disease treatments.

As Novartis continues to refine its oncology pipeline, the company is expected to apply similar market access frameworks to its next generation of cell therapies. This involves not only pricing but also creating the patient identification systems necessary to find the rare disease populations that qualify for these specific genetic interventions.